DBS for epilepsy therapy launchedApril 9, 2019
Medtronic has launched Deep Brain Stimulation (DBS) for medically-refractory epilepsy in the US.
DBS therapy uses a surgically implanted medical device for epilepsy. It delivers controlled electrical pulses to a target in the brain called the anterior nucleus of the thalamus (ANT), which is part of a network involved in seizures.
Recently, the US FDA granted pre-market approval for Medtronic DBS therapy for epilepsy as an adjunctive treatment for reducing the frequency of partial-onset seizures in individuals 18 years of age or older who are refractory, or drug-resistant, to three or more antiepileptic medications.
The approval was based on results from the SANTE (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy) trial, wherein patients had a median seizure frequency reduction of 75 percent at seven years post-implant.
Similar to a cardiac pacemaker, it delivers electrical stimulation to precisely targeted areas of the brain as adjunctive treatment for several neurological disorders.
In addition to medically refractory epilepsy, DBS therapy is currently approved in many locations around the world, including the US and Europe, for the treatment of the disabling symptoms of essential tremor and recent and longer-standing Parkinson’s disease. The device is also useful to treat chronic intractable primary dystonia and severe, treatment-resistant obsessive-compulsive disorder, the company said.